Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Centanafadine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Otsuka Presents Centanafadine Phase 3 ADHD Data at ASCP
    Otsuka Presents Centanafadine Phase 3 ADHD Data at ASCP

    28 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260528411791/en/Otsuka-Presents-New-Phase-3-Post-Hoc-Analyses-of-Centanafadine-Highlighting-Improvement-in-Executive-Function-and-Emotional-Dysregulation-in-Adults-with-ADHD-at-the-2026-American-Society-of-Clinical-Psychopharmacology-ASCP-Annual-Meeting

    BUSINESSWIRE
    28 May 2026
    Share Share
    Otsuka Seeks FDA Priority Review For Centanafadine In ADHD
    Otsuka Seeks FDA Priority Review For Centanafadine In ADHD

    27 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260127432877/en/Otsuka-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Centanafadine-for-the-Treatment-of-ADHD-in-Children-Adolescents-and-Adults

    BUSINESSWIRE
    27 Jan 2026
    Share Share
    Otsuka Pharma Seeks FDA Approval For Centanafadine In ADHD
    Otsuka Pharma Seeks FDA Approval For Centanafadine In ADHD

    24 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251124043308/en/Otsuka-Pharmaceutical-Submits-New-Drug-Application-to-U.S.-FDA-for-Centanafadine-for-the-Treatment-of-ADHD-in-Children-Adolescents-and-Adults

    BUSINESSWIRE
    24 Nov 2025
    Share Share
    Otsuka reports positive results from two phase 3 trials of centanafadine
    Otsuka reports positive results from two phase 3 trials of centanafadine

    30 Oct 2023

    // PHARMABIZ

    http://pharmabiz.com/NewsDetails.aspx?aid=163285&sid=2

    PHARMABIZ
    30 Oct 2023
    Share Share
    Otsuka Announces Positive Results From Phase 3 Trials of Centanafadine
    Otsuka Announces Positive Results From Phase 3 Trials of Centanafadine

    27 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231027187786/en

    BUSINESSWIRE
    27 Oct 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.